Regulatory issues on both sides of the Atlantic held back growth at Sanofi’s Consumer Healthcare business in the third quarter as sales edged up by 0.4% at constant exchange rates to €1.14bn ($1.27bn).
Zantac Recall And EU Regulatory Issues Hurt Sanofi In Q3
Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.
